SCHEMBL4066627

SCHEMBL4066627

Cc1ccc(-c2cc3ncnc(N(C)c4ccc5c(c4)OCO5)c3s2)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CLK4 Q9HAZ1 11/20 0.47
ALDH1A1 P00352 3/20 0.47
CYP1A2 P05177 3/20 0.47
CYP3A4 P08684 3/20 0.47
CYP2D6 P10635 3/20 0.47
CYP2C19 P33261 3/20 0.47
LMNA P02545 2/20 0.47
TSHR P16473 2/20 0.47
MAPK1 P28482 2/20 0.47
HSD17B10 Q99714 2/20 0.47
HIF1A Q16665 1/20 0.47
CLK1 P49759 9/20 0.43
CLK2 P49760 9/20 0.43
DYRK1A Q13627 9/20 0.43
DYRK1B Q9Y463 9/20 0.43
CLK3 P49761 6/20 0.43
CDK2 P24941 1/20 0.43
EGFR P00533 4/20 0.43
PDGFRB P09619 1/20 0.43
PDGFRA P16234 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3938276 0.93 CLK4 (0.51) CLK4ALDH1A1CYP1A2CYP3A4CYP2D6
SCHEMBL4075078 0.92 CLK4 (0.45) CLK4ALDH1A1CYP1A2CYP3A4CYP2D6
SCHEMBL4075049 0.91 MAP3K8 (0.45) CLK4ALDH1A1CYP1A2CYP3A4CYP2D6
SCHEMBL4069658 0.91 EGFR (0.47) CLK4ALDH1A1CYP1A2CYP3A4CYP2D6
SCHEMBL4068416 0.91 TYK2 (0.49) CLK4ALDH1A1CYP1A2CYP3A4CYP2D6
SCHEMBL4064210 0.91 CLK4 (0.47) CLK4ALDH1A1CYP1A2CYP3A4CYP2D6
SCHEMBL4071470 0.89 CLK4 (0.45) CLK4ALDH1A1CYP1A2CYP3A4CYP2D6
SCHEMBL4064459 0.89 KMT2A (0.52) CLK4ALDH1A1CYP1A2CYP3A4CYP2D6
SCHEMBL3930446 0.87 CLK4 (0.43) CLK4ALDH1A1CYP1A2CYP3A4CYP2D6
SCHEMBL4071119 0.87 CLK4 (0.43) CLK4ALDH1A1CYP1A2CYP3A4CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090042878-A1 THIENOPYRIMIDYLAMINES AS MODULATORS OF THE EP2 RECEPTOR BAYER SHERING PHARMA AG (DE) 2009-02-12 US claimed
EP-2014663-A1 Thieno-pyrimidyl amines as modulators of EP2 receptors Bayer Schering Pharma AG (DE) 2009-01-14 EP claimed
US-20090042878-A1 THIENOPYRIMIDYLAMINES AS MODULATORS OF THE EP2 RECEPTOR BAYER SHERING PHARMA AG (DE) 2009-02-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090042878-A1 THIENOPYRIMIDYLAMINES AS MODULATORS OF THE EP2 RECEPTOR PTGER2, PTGER1, PTGDR2 CLK4 4484/4885ALDH1A1 1167/4885CYP1A2 137/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.